Autologous Mesenchymal Stem Cells for Treatment of Chronic Active Antibody-Mediated Kidney Graft Rejection: Report of the Phase I/II Clinical Trial Case Series

Mesenchymal stem cell (MSCs) therapy has already been studied in kidney transplant recipients (KTRs), and the available data showed that it is safe and well tolerated. The aim of this study was to evaluate the safety and efficacy of autologous MSCs in combination with standard therapy in KTRs with b...

Descripción completa

Detalles Bibliográficos
Autores principales: Večerić-Haler, Željka, Sever, Matjaž, Kojc, Nika, Halloran, Philip F., Boštjančič, Emanuela, Mlinšek, Gregor, Oblak, Manca, Poženel, Primož, Švajger, Urban, Hartman, Katrina, Kneževič, Miomir, Barlič, Ariana, Girandon, Lenart, Aleš Rigler, Andreja, Zver, Samo, Buturović Ponikvar, Jadranka, Arnol, Miha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Health Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722440/
https://www.ncbi.nlm.nih.gov/pubmed/36484064
http://dx.doi.org/10.3389/ti.2022.10772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722440/
https://www.ncbi.nlm.nih.gov/pubmed/36484064
http://dx.doi.org/10.3389/ti.2022.10772

Ejemplares similares